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I-61 The changing molecular epidemiology of
hepatitis A virus infection in Jerusalem following
implementation of universal vaccination in
1999 2004
D. Shouval1 *, N. Daudi1, G. Xia2, O. Nainan2, H. Margolis2,
J. Kark3, A. Ben-Nun4, B. Bell2, R. Dagan5, Y. Ashur1. 1Liver
Unit and and 3Dept of Epidemiology, Hadassah-Hebrew
University (HUJI), Jerusalem, Israel, 2Centers for
Disease Control and Prevention, Atlanta, Georgia, USA,
4GIS Center, HUJI, Jerusalem; 5Soroka Medical Center,
Beer-Sheba, Israel
Universal vaccination against hepatitis A was introduced in
Israel in July 1999 by immunization of 18 month old toddlers
with one booster at 24 months. Efﬁcacy of the vaccination
program was monitored through active surveillance in the
district of Jerusalem and a passive national surveillance
system in the entire country. In 2002, the Jerusalem district
population consisted of 732,163 Jewish and 205,000 non-
Jewish (mainly Arab of Moslem and Christian background)
inhabitants. Between 1999 and 2005, a total of 2010
patients were identiﬁed in the Jerusalem district with
anti-HAV IgM+, acute HAV infection, out of whom 848
underwent HAV-RNA analysis by PCR (VP1-P2B, 325 bp).
HAV-RNA was detected in 709/848 patients tested (84%),
with 387 patients being infected with HAV genotype 1a and
322 with HAV 1b. I97% of the genotype 1a subjects belong
to the Jewish population while 72% of the genotype 1b
subjects belong to the non-Jewish population. A Geographic
Information System (GIS) program was utilized to map the
various HAV clusters and subtypes. Analysis of the GIS data
revealed that genotype 1a was almost exclusively present in
isolated orthodox Jewish communities (97%), characterized
by crowding and low socio-economic conditions. Genotype
1b was mainly detected in the non-Jewish population
living under similar low socio-economic conditions (82%).
However, 18% of genotype 1b isolates were obtained from
a Jewish secular population residing in the western part of
the city who probably have contact with the non-Jewish
population. In summary, the distribution of the various HAV
clusters reﬂects the distinct socio-economic, cultural and
geographic population patterns in the city of Jerusalem.
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Objectives: To investigate the age-speciﬁc prevalence
of HPV infections among women in different Chinese
populations and generate data useful in the prevention
of cervical cancer by prophylactic vaccine in China.
Methods: A population-based, cross-sectional study of
Chinese women took place in the 4 rural counties (Xinmi,
Xiangyuan, Yangcheng and Yutian) and 4 cities (Beijing,
Shanghai, Shenzhen and Shenyang) between May 2004 and
April 2007. Total of 6099 female participants were sampled
within eight 5-year age groups between 15- and 54- years
of age. Cervical samples were tested with Hybrid Capture
II (hc2, Digene) for both high and low-risk HPV types. All
HPV positive patient samples and 10% of HPV negative
samples underwent genotyping using Linear Array (Roche)
or GP5+/6+-based PCR assay for 44 HPV types.
Results: Mean age of the study participants was 37 years.
Most women surveyed were married (99.2%) and non-
smokers (97.3%). HR-HPV prevalence was 13.2% overall and
8.74% among women without cervical abnormalities. The
HR HPV positive rate of Han Majority people was double
than Uygur Minority (Xinjiang), 14.2% (740/5216) vs. 7.2%
(64/883). HR HPV age-speciﬁc rates in Han Majority were
(20 24) 15.5%; (25 29) 12.9%; (30 34) 13%; (35 39) 12.5%;
(40 44) 16.1%; (45 49) 15% and (50 ) 14.6% and were similar
in all age groups. All low risk HPV and HPV genotyping
stratiﬁed by geographic areas and different population are
still analyzing. The results of HPV distribution and the
population characteristic such as education, sexual habits,
reproductive history or use of contraceptive methods will
be reported.
Conclusions: This will be the ﬁrst report of large
population-based multi-center survey in China. These
results on the prevalence and distribution of HPV types in
different geographic areas will have implications for future
cervical cancer screening and health resources allocation,
particularly in regards to the future applications of HPV
prophylactic vaccine.
I-63 Development of therapeutic vaccine against HBV
by the use of adjuvant to boost the cell-mediated
immunity
B. Wang, W.J. Zhang, X.G. Du. State Key Laboratory
for Agro-Biotechnology, Department of Microbiology
and Immunology, College of Biological Science, China
Agricultural University, Beijing 100193, China
Therapeutic vaccine against chronical HBV infection is an
attractive strategy. The CpG ODN as a Toll-like receptor 9
(TLR 9) agonist has been shown to be a potent adjuvant
for promoting the cell-mediated response in animals and
considered as candidate adjuvant for the therapeutic
vaccine. Recently, however, its efﬁcacy in human trials is
in questioning. Although several other similar adjuvants are
under developed, their potency and particular the safety
are under serious scrutiny.
We recently develop a simple approach by the re-discovery
of adjuvant functions on the existing medical drugs in
the market, of which can either activate TLR pathways
or remove the blockade of immune response to be used
as potential adjuvant(s) for such therapeutic strategy.
Two chemical compounds Levamisole (LMS), anti-parasites
in animals and human over 30 years, and Cimetidine
(CIM), a histamine 2-receptor antagonist to treat stomach
acid, have been demonstrated to have adjuvant potentials
in our previously studies. The LMS can up-regulate the
expression of TLR7&8, MyD88, IRF7 and their downstream
pro-inﬂammatory cytokines including IFN-a and TNF-a and
promote DCs activation. With HBV subunit vaccine together,
LMS induces robust cell-mediated responses evaluated
by the higher level of IgG2a, T cell proliferation, and
importantly, signiﬁcant higher level of antigen speciﬁc
cytotoxic response in vivo and IFN-g production within
the CD8+ T cells. On the other hand, CIM can impair
CD4+CD25+ Treg cell-mediated immune suppression by
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down-regulating the expressions of IL-10 and TGF-b, anti-
inﬂammatory cytokine, and promoting the IL-12 expression,
pro-inﬂammatory cytokine. With HBV subunit vaccine, CIM
can also enhance antigen speciﬁc cell-mediated response in
animals.
The combination of LMS and CIM can synergistically enhance
the immunogenicity of HBV subunit vaccine and leads to a
robust at a comparative level achieved with CpG+alum in
animals. Since the safety proﬁle of the two chemicals, their
combination with the HBV subunit vaccine may provide a
cost effective and safe, yet effective therapy to treat those
individuals chronically infected by HBV.
Concurrent Session 13 Viral Hepatitis and
Hepatocellular Carcinoma
I-64 Viral factors of hepatocellular carcinoma in chronic
hepatitis B
H.L.Y. Chan*. The Chinese University of Hong Kong, China
Chronic hepatitis B is the commonest cause of
hepatocellular carcinoma (HCC) in Asia. Various clinical
factors including older age, male gender, positive HBeAg
and liver cirrhosis have been suggested to associate with
a higher risk of HCC. Higher HBVDNA has been shown by
various longitudinal studies to associate with a higher risk of
liver cirrhosis and HCC. We have performed a longitudinal
study comparing the serial HBVDNA among patients who
developed and did not develop HCC. The trough HBVDNA
level seemed to be the most important determinant of HCC
development.
We have performed a prospective longitudinal study among
426 chronic hepatitis B patients with a follow-up up to
5 years. Genotype C HBV is found to be an independent risk
factor of HCC over genotype B HBV. This is probably related
to the more active liver disease and higher proportion of
basal core promoter mutations related to genotype C HBV.
In another study including 1006 patients followed up for
over 7 years, HBV subgenotype Ce was found to associate
with highest risk of HCC independent of HBVDNA levels.
To further investigate the virological mechanism of HCC by
different HBV genotypes/subgenotypes, we have performed
full genome sequencing of the HBV in 100 chronic hepatitis B
patients with HCC and another 100 patients without
HCC. Different viral genotypes and subgenotypes have
different viral genomic markers for HCC. After data mining,
algorithms can be derived with a sensitivity of HCC
prediction of 70% 80%.
I-65 Hepatitis B and C viral cellular interactions in the
pathogenesis of hepatocellular carcinoma
J.R. Wands*. The Liver Research Center, Rhode Island
Hospital and the Warren Alpert Medical School of Brown
University, Providence, Rhode Island, USA
On a global scale, chronic hepatitis B virus (HBV) and
hepatitis C virus (HCV) account for well over 90% of
hepatocellular carcinoma (HCC). Our Liver Research Center
has been interested in viral-cellular protein interactions
that may be responsible for this exceedingly high risk of
hepatocyte transformation during persistent viral infection
and how anti-viral agents may reduce this risk. There
are two major signal transduction pathways that appear
to be activated in most HCC and may occur very early
in the disease process such as in dysplastic hepatocytes.
The ﬁrst is the insulin/IGF-1/IRS-1 signal transduction
pathway involved in hepatocyte growth and survival. The
other major signaling pathway involves the Wnt/Frizzled/b-
catenin cascade involved in cell migration and proliferation
normally “on” during embryonic development. However,
aberrant activation of this pathway in adults can lead to
tumor formation through its stimulatory effects on cell
migration, invasion, and cell proliferation.
Finally, we will discuss recent reports that demonstrate
interactions of HCV and HBV structural and non-structural
proteins on various components of these two pathways that
tend to promote activation during chronic viral infection.
A further understanding of the interaction of viral and
hepatocyte-derived cellular proteins will provide insights
into the molecular mechanisms of HBV and HCV related HCC
and begin to deﬁne the critical role of these interactions in
the transformation process. These studies describe essential
molecular mechanisms that may serve as targets for
possible therapeutic intervention in addition to approaches
that reduce viral replication and persistence via anti-viral
agents.
I-66 How to predict HCC development in patients with
chronic hepatitis B viral infection?
K.H. Han*. Department of Internal Medicine and Liver
Cirrhosis Clinical Research Center, , Yonsei University
College of Medicine, Seoul, Korea
Hepatocellular carcinoma (HCC) is one of the major
malignant diseases in Asia. The incidence rates of HCC
geographically differ according to high prevalence of
hepatitis B virus (HBV) infection.
Chronic necro-inﬂammation by persistent HBV infection can
progress to cirrhosis and meanwhile genetic changes can
lead to the occurrence of HCC. Long standing inﬂammatory
activities may play an important role in the clinical course
of HBV infection. We studied 188 patients with chronic
hepatitis B for a mean of 80.6 months to evaluate the long-
term outcome of chronic hepatitis B patients, based on the
histological grade and stage, in Korea. The development of
cirrhosis correlated well with the grade of porto-periportal
activity and stage of ﬁbrosis (p < 0.05). Patients with a higher
grade of porto-periportal activity and higher stage of ﬁbrosis
had a greater chance of developing cirrhosis. Based on ALT
levels during follow-up, we classiﬁed the patients into active
and inactive biochemical hepatitis groups. The probabilities
of developing cirrhosis, decompensation, and HCC were
signiﬁcantly higher in the active biochemical hepatitis group
(p < 0.01). Multivariate analysis showed that the prognostic
factors for developing cirrhosis and decompensation were
age and biochemical hepatitis activity during follow-up.
From our follow-up study, we can conclude that
development of cirrhosis correlated well with the grade
of porto-periportal activity and stage of ﬁbrosis at liver
biopsy. In addition, biochemical hepatitis activity during the
follow-up was an independent prognostic factor affecting
the long-term outcome of chronic hepatitis B. Therefore,
effective control of hepatitis activity might improve the
long-term outcome of chronic hepatitis B patients.
In high endemic areas of chronic HBV infection, a screening
program to detect HCC development conﬁned to the
patients with chronic B viral liver disease is necessitated.
The cost-effectiveness of a screening program could
probably be increased further by focusing the screening
of patients according to the risk factors most likely to
affect them. Therefore, it is very important to assess the
risk factors of HCC development. We demonstrated that
the more risk factors, the higher HCC development. A
tailored screening system with individual prediction model
for HCC was also proposed based on relative signiﬁcance
of risk factors and prospectively conﬁrmed. Recent our
study of 688 patients with chronic B viral liver diseases
